Research Summary

I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.

Clinically, I see patients in the Cancer Immunotherapy Program where I am an attending physician, principal investigator, and co-investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.

In the laboratory, I study samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.

Research Funding

  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375
  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375
  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375
  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH, Sponsor Award ID: K08AI139375

Education

Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology

Honors & Awards

  • 9/2001-6/2011
    Medical Scientist Training Program awardee
  • 3/2010
    Keystone Symposia Travel Scholarship
  • 6/2015
    UCSF Hematology/Oncology Clinical Fellow Award (selected by Medicine housestaff for patient care, teaching, professionalism)
  • 1/2016
    UCSF Hematology/Oncology 2016 Award for Excellence in Fellowship Research
  • 4/2016
    Merit Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 6/2017
    Young Investigator Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 5/2018
    Young Investigator Award, Bladder Cancer Advocacy Network
  • 7/2018
    Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin V TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.  View on PubMed
  2. Baik AH, Tsai KK, Oh DY, Aras MA Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.  View on PubMed
  3. Oh DY CD38 as a Novel Immunosuppressive Target in Prostate Cancer.  View on PubMed
  4. Vadim S Koshkin, Divya Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.  View on PubMed
  5. Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou, David Yoonsuk Oh, Raj Pruthi, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.  View on PubMed
  6. Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.  View on PubMed
  7. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY Autoantibody Landscape in Patients with Advanced Prostate Cancer.  View on PubMed
  8. Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.  View on PubMed
  9. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.  View on PubMed
  10. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.  View on PubMed
  11. Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.  View on PubMed
  12. Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk Oh, Rahul Raj Aggarwal, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.  View on PubMed
  13. Daniel Kwon, Francis Wright, Li Zhang, Jonathan Chou, Hala Borno, Arpita Desai, David Yoonsuk Oh, YaoYao Guan Pollock, Rohit Bose, Franklin W. Huang, Thomas Hope, Terence W. Friedlander, Lawrence Fong, Felix Y Feng, Eric Jay Small, Rahul Raj Aggarwal, Vadim S Koshkin Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.  View on PubMed
  14. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.  View on PubMed
  15. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.  View on PubMed
  16. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.  View on PubMed
  17. Oh DY, Fong L Immunity in the Time of Metastases.  View on PubMed
  18. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.  View on PubMed
  19. Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire  View on PubMed
  20. David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients.  View on PubMed

Go to UCSF Profiles, powered by CTSI